Success Metrics

Clinical Success Rate
78.9%

Based on 15 completed trials

Completion Rate
79%(15/19)
Active Trials
1(4%)
Results Posted
20%(3 trials)
Terminated
4(14%)

Phase Distribution

Ph phase_2
10
36%
Ph phase_1
2
7%
Ph not_applicable
14
50%
Ph phase_3
2
7%

Phase Distribution

2

Early Stage

10

Mid Stage

2

Late Stage

Phase Distribution28 total trials
Phase 1Safety & dosage
2(7.1%)
Phase 2Efficacy & side effects
10(35.7%)
Phase 3Large-scale testing
2(7.1%)
N/ANon-phased studies
14(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

78.9%

15 of 19 finished

Non-Completion Rate

21.1%

4 ended early

Currently Active

1

trials recruiting

Total Trials

28

all time

Status Distribution
Active(4)
Completed(15)
Terminated(4)
Other(5)

Detailed Status

Completed15
unknown5
Terminated4
Not yet recruiting2
Recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
28
Active
1
Success Rate
78.9%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (7.1%)
Phase 210 (35.7%)
Phase 32 (7.1%)
N/A14 (50.0%)

Trials by Status

unknown518%
recruiting14%
terminated414%
enrolling_by_invitation14%
not_yet_recruiting27%
completed1554%

Recent Activity

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT07530965Not Applicable

OMEGA-3-FATTY ACIDS IN CHILDREN WITH SICKLE CELL DISEASE

Not Yet Recruiting
NCT06911060Not Applicable

Flaxseed Consumption on Biochemical and Quality of Life in Type 2 Diabetes

Not Yet Recruiting
NCT05088863Not Applicable

Survey Assessing How Consumers Adapt Their Diet in Response to Health Claim Messaging

Recruiting
NCT06683235Not Applicable

Effect of Flaxseed as a Treatment for Adults With Type 2 Diabetes Mellitus in Mexico

Enrolling By Invitation
NCT03183102Not Applicable

The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.

Completed
NCT05245825Not Applicable

Flaxseed Supplementation in Prediabetic Adults (LINAPRED)

Unknown
NCT01698294Not Applicable

Biomarkers in Post-Menopausal Women Receiving Flaxseed

Completed
NCT01952340Phase 2

The Efficacy of Dietary Flaxseed for the Reduction of Blood Pressure in Newly Diagnosed Hypertensive Individuals

Terminated
NCT02475330Phase 2

Dietary Flaxseed in NSCLC

Terminated
NCT00955942Phase 1

Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy

Terminated
NCT04024605Not Applicable

Bioavailability of Protein and Amino Acids From Oilseeds in Healthy Volunteers

Unknown
NCT03915600Not Applicable

Efect of Quinoa and Flaxseed in Cititoxicity and Glicemic Control in Metabolic Syndrome Patients

Unknown
NCT03734835Not Applicable

The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Metabolic Syndrome

Unknown
NCT03392025Not Applicable

Flaxseed Consumption, Alone and in Combination With the Mediterranean-like Diet, on Some Indicators Related to Atherosclerosis

Completed
NCT03036722Not Applicable

Flaxseed Consumption and Bone Metabolism in Postmenopausal Women.

Unknown
NCT00612560Not Applicable

Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics

Completed
NCT00956813Phase 3

Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

Completed
NCT00049309Phase 2

Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer

Completed
NCT00781950Phase 2

Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease

Completed
NCT02395900Phase 2

The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
28